Europe’s health policies ‘must change’ with stakeholders leaving their ‘comfort zones’
24 Oct 2014
“Patients are waiting for therapeutic improvement and asking us – while we have good technologies – are we really bringing them the best new drugs? And if we look hard in the mirror the fact is that we are not using technology optimally”, said Dr. Denis Lacombe, EORTC Director. “There needs to be more collaboration, new models…and that means we have to think outside the box.”
Read the entire interview here
Related News
First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer
28 Oct 2026
EORTC at ESMO 2026: New findings and ongoing studies
27 Oct 2026
EORTC research presented at ESMO 2026
22 Oct 2026
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
Final results of ARCAGEN – An EORTC-SPECTA and EURACAN initiative for molecular profiling and access to treatment for rare cancers
23 Jul 2026
